Midatech Pharma PLC (LSE:MTPH) - Share price - Overview

Stock Report

Midatech Pharma PLC MTPH

Last Price
GBX108.50

Day Change
-0.50|-0.46%

As of 26/05/2017
13:52:06 BST | GBX
Minimum 15 Minutes Delay.

Last Close109.00p
Day Range108.00 - 108.00
Mkt Cap53.10Mil
52-Wk Range100.51 - 189.90
Yield %0.00
ISINGB00BRTL9B63
Volume3,305
P/E-4.45
P/S5.65
P/CF-3.01

Share Price

Total Returns 26/05/2017

 Chg (%)  
More ...
Midatech Pharma PLC-7.66 
FTSE 100 TR GBP3.92
 
Financials
201420152016
More ...
Income Statement
Turnover0.161.386.92
Operating Profit-9.69-12.92-30.59
Net Profit-8.82-10.10-20.16
Reported EPS-98.00-36.00-56.00
Balance Sheet
Current Assets31.6320.3322.30
Non Current Assets15.0443.7134.39
Total Assets46.6664.0456.69
Current Liabilities2.839.109.35
Total Liabilities4.6717.1510.97
Total Equity41.9946.8945.72
Cash Flow
Operating Cash Flow-6.25-13.07-14.74
Net Change in Cash27.94-14.170.97
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
2017-13.87-26.60--4.10---
2018-10.09-19.35--5.63---
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
20/12/2016PurchaseDr. Jim Phillips110.0013,38014,718.00
19/12/2016Transfer OutDr. Jim Phillips0.007,9000.00

Company Profile

Midatech Pharma PLC is a nanomedicine company engaged in the development and commercialization of multiple therapeutic products to enhance the delivery of medicines in diseases with high unmet medical needs.

Sector

Biotechnology

Market Position

1106 of 1850 Companies

Index

FTSE AIM All Share

Outlook

(10/04/2017) ceo - "We are well placed to deliver further growth"

Next Event 04/09/2017

Next interim announcement
Ratios
CompSecMkt
More ...
PER (E)-4.5914.9716.81
Div Yld (E)0.003.624.07
PEG (E)0.000.410.76
ROCE-106.74187.7717.40
Op Mrgn-260.00-6.68-91.76
EPS Grwth0.0057.2727.18
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanMr. Rolf Stahel
Chief Executive OfficerDr. Jim Phillips
Finance Director & Company SecretaryMr. Nick Robbins-Cherry
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.